GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation [Yahoo! Finance]
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Yahoo! Finance
GSK plc (NYSE:GSK) is one of the largest pharmaceutical companies in the world. The firm scored a major win on December 10th after the Food and Drug Administration (FDA) granted its lung cancer drug risvutatug rezetecan the Orphan Drug Designation. Such a designation allows drugs with small target populations to receive financial incentives, such as tax breaks, to spur research and development. GSK plc (NYSE:GSK)'s risvutatug rezetecan, also called the GSK'227, received the FDA's designation after its phase 1 clinical trials called ARTEMIS-001 showed positive responses in patients with serious small-cell lung cancer. GSK plc (NYSE:GSK) also shared additional details about the small-cell lung cancer (SCLC) market. According to the firm, this cancer accounts for 13% of all cancers in America, with 29,500 people expected to be diagnosed with the disease. Copyright: kadmy / 123RF Stock Photo Investment bank JPMorgan kept a Sell rating and a £17 share price target for GSK plc (NYSE:GS
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK (NYSE:GSK) had its "reduce" rating reaffirmed by analysts at HSBC Holdings plc.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- GSK (NYSE:GSK) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Deutsche Bank Maintains a Hold Rating on GSK plc (GSK) [Yahoo! Finance]Yahoo! Finance
GSK
Sec Filings
- 12/12/25 - Form 6-K
- 12/12/25 - Form 6-K
- 12/12/25 - Form 6-K
- GSK's page on the SEC website